LEADER 01564oam  2200385Ia 450 
001 9910698991403321
005 20090611160429.0
035   $a(CKB)5470000002397958
035   $a(OCoLC)388281444
035   $a(EXLCZ)995470000002397958
100   $a20090611d2006      ua             0
101 0 $aeng
135   $auran|||||||||
181   $ctxt$2rdacontent
182   $cc$2rdamedia
183   $acr$2rdacarrier
200 00$aGuidance for industry and FDA staff$b[electronic resource] $eearly development considerations for innovative combination products
210  1$aRockville, MD :$cU.S. Dept. of Health and Human Services, Food and Drug Administration, Office of the Commissioner, Office of Combination Products,$d[2006]
215   $a13 pages $cdigital, PDF file
300   $aTitle from PDF title page (viewed on June 11, 2009).
517   $aGuidance for industry and FDA staff 
606   $aMedical instruments and apparatus$xGovernment policy$zUnited States
606   $aDrug development$xGovernment policy$zUnited States
606   $aBiological products$xGovernment policy$zUnited States
615  0$aMedical instruments and apparatus$xGovernment policy
615  0$aDrug development$xGovernment policy
615  0$aBiological products$xGovernment policy
712 02$aUnited States.$bFood and Drug Administration.$bOffice of Combination Products.
801  0$bGPO
801  1$bGPO
801  2$bGPO
906   $aBOOK
912   $a9910698991403321
996   $aGuidance for industry and FDA staff$93451983
997   $aUNINA